Research
Hormonal
Visceral adipose tissue accumulation is causally linked to hepatic insulin resistance and increased cardiometabolic risk, whereas subcutaneous adipose tissue accumulation is metabolically protective.
Prioritize strategies that promote subcutaneous fat storage (like lower-body resistance training) over those that might increase visceral fat. Monitor waist circumference and metabolic markers (blood sugar, lipids) rather than just total body weight, as visceral fat is the primary driver of metabolic disease.
GoodSupportsHIGH confidence
individuals with central obesity are more susceptible to developing diabetes and cardiovascular complications, whereas those with peripheral obesity are more metabolically healthy.
Why this rating
Based on a comprehensive review of human association studies, animal models, and transplantation studies.
Source
Heterogeneity of white adipose tissue: molecular basis and clinical implications
Kelvin H. M. Kwok et al. · Experimental & Molecular Medicine · 2016
DOI 10.1038/emm.2016.5
narrative_reviewCited 236×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Visceral adipose tissue promotes insulin resistance through the Portal Theory, where NEFAs and cytokines drain directly to the liver, whereas subcutaneous fat drains systemically and is diluted.Good
- Subcutaneous adipose tissue, particularly in the gluteal-femoral region, acts as a metabolically protective 'sink' for lipids, preventing ectopic deposition in vital organs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →